References:
1. Nplate® (romiplostim) prescribing
information, Amgen.
2. Newland A, Godeau B, Priego V, et al. Remission and
platelet responses with romiplostim in primary immune thrombocytopenia:
final results from a phase 2 study.
Br J Haematol. 2016;172(2):262-273.
3. Data on file, Amgen; Clinical Study Report 20080435;
2014.
4. Data on file, Amgen; Number of patients treated with
Nplate® from launch through to June 2023; Updated 2023.
5. Data on file, Amgen; Time to Onset, biostatistical
analysis; 2019.
6. Neunert C, Terrell DR, Arnold DM, et al. American
Society of Hematology 2019 guidelines for immune thrombocytopenia.
Blood Adv. 2019;3(23):3829-3866.
7. Rituxan® (rituximab) full Prescribing
Information, Genentech.
8. Lozano ML, Mingot-Castellano ME, Perera MM, et al.
Deciphering predictive factors for choice of thrombopoietin receptor
agonist, treatment free responses, and thrombotic events in immune
thrombocytopenia. Sci Rep. 2019;9(1):16680.
9. Newland A, Godeau B, Priego V, et al. Remission and
platelet responses with romiplostim in primary immune thrombocytopenia:
final results from a phase 2 study. Br J Haematol.
2016;172(Suppl):1-4.
10. Promacta® (eltrombopag) full Prescribing
Information, Novartis.
11. Doptelet® (avatrombopag) full Prescribing
Information, Sobi.
12. Tavalisse® (fostamatinib disodium
hexahydrate) full Prescribing Information, Rigel.
13. Kuter DJ, Bussel JB, Newland A, et al. Long-term
treatment with romiplostim in patients with chronic immune thrombocytopenia:
safety and efficacy. Br J Haematol. 2013;161(3):411-423.
14. Gilani B, Cassagnol M. Biochemistry, Cytochrome P450. In: StatPearls
[Internet]. Treasure Island (FL): StatPearls Publishing; January 2024.
https://www.ncbi.nlm.nih.gov/books/NBK557698/.
15. Data on file, Amgen; Nplate® IQVIA LAAD 2021 and 2022 OOP Cost Analysis Medicare Commercial Combined ALL; 2023.
16. Data on file, Amgen; Nplate® - coverage from MMIT; 2023.